ホーム › マントル細胞リンパ腫 › オハイオ
オハイオにおけるマントル細胞リンパ腫の臨床試験
オハイオ内の拠点で、マントル細胞リンパ腫に関する16件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第3相
60歳以上 · 全性別 · 2026/10/02更新 · NCT05976763A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- University Hospitals, Cleveland
- Cleveland Clinic Foundation, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06742996A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07003295Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06564038Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579DALY II USA/ MB-CART2019.1 for DLBCL
- The Ohio State University Wexner Medical Center James Cancer, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/22更新 · NCT03523975The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- University of Cincinnati, Cincinnati
- Ohio State University, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT04775745AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Taylor Cancer Research Center, Maumee
被験者募集中第1相
18歳以上 · 全性別 · 2025/12/10更新 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University Hospitals Cleveland Medical Center, Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/02更新 · NCT05780034ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。